Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed, directly or indirectly, in the United States or any other jurisdiction where such release or distribution might be unlawful. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase, or subscribe for any securities of the Company.

*This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions where such offer is unlawful. The Company's shares mentioned in this announcement have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**") and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.*

Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

CLOSING OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE

Joint Placing Agents

CICC 中金公司　　兴证国际 INDUSTRIAL SECURITIES INTERNATIONAL

Reference is made to the announcement of Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司) (the "**Company**") dated 14 January 2026 (the "**Announcement**") in relation to the placing of new H shares under the general mandate. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

CLOSING OF PLACING

The Board is pleased to announce that all the conditions set out in the Placing Agreement have been fulfilled and the Closing took place on 22 January 2026 in accordance with the terms and conditions of the Placing Agreement. A total of 35,200,000 Placing Shares have been successfully placed by the Placing Agent to no less than six Placees at the Placing Price of HK$26.00 per Placing Share pursuant to the terms and conditions of the Placing Agreement, representing (i) approximately 33.78% of the number of existing issued H Shares and 20.00% of number of existing issued Shares immediately before the Closing; and (ii) approximately 25.25% of the number of issued H Shares and approximately 16.67% of the number of issued Shares immediately upon the Closing as at the date of this announcement.

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, (i) each of the Placees and their respective ultimate beneficial owners are third parties independent of, and not connected with, the Company and its connected persons; and (ii) none of the Placees has become a substantial shareholder immediately after the Closing.

The Company will timely fulfil the corresponding filing procedures in respect of the Placing in accordance with the CSRC Rules.

USE OF PROCEEDS

The gross proceeds and net proceeds (after deducting the Placing commission and other relevant costs and expenses of the Placing) from the Placing, are approximately HK$915.20 million and HK$884.31 million, respectively, representing a net issue price of HK$25.12 per Placing Share. As disclosed in the Announcement, such net proceeds are currently intended to be applied as follows: (a) approximately 56.54% or HK$500.00 million for funding the Company's continued expansion of product portfolios through investment and potential acquisition in the medical devices industry; (b) approximately 23.75% or HK$210.00 million for repayment of existing interest-bearing bank borrowings; and (c) approximately 19.71% or HK$174.31 million for the Company's working capital and other general corporate purposes including staff costs and day-to-day operational expenses. The net proceeds from the Placing are expected to be fully utilized by 2027. Such expected time frame is based on the Board's best assessment, and is subject to adjustment depending on

the Company's future development, market conditions and prevailing business circumstances. As at the date of this announcement, the Group has not identified any specific target for investment and acquisition in the medical devices industry.

EFFECTS OF THE PLACING ON SHAREHOLDING STRUCTURE OF THE COMPANY

As at the date of this announcement, the total number of issued Shares is 211,200,000 Shares, comprising 139,413,392 H Shares and 71,786,608 Domestic Shares.

The table below sets out the changes to the shareholding structure of the Company as a result of the Closing:

	Immediately before the Closing		**Immediately upon the Closing**	
Shareholders	*Number of issued Shares*	*Approximate percentage in the issued share capital of the Company[(1)] (%)*	*Number of issued Shares*	*Approximate percentage in the issued share capital of the Company[(1)] (%)*
Domestic Shares				
Core connected persons[(2)]	51,643,748	29.34	51,643,748	24.45
Other Domestic Shareholders	20,142,860	11.44	20,142,860	9.54
Total number of Domestic Shares	**71,786,608**	**40.79**	**71,786,608**	**33.99**
H Shares				
Core connected persons[(3)]	74,195,592	42.16	74,195,592	35.13
Mr. Ke Wei (柯偉)	6,070,000	3.45	8,540,000	4.04
Other Placees	—	—	32,730,000	15.50
Other H Shareholders	23,947,800	13.61	23,947,800	11.34
Total number of H Shares	**104,213,392**	**59.21**	**139,413,392**	**66.01**
Total number of Shares	**176,000,000**	**100.00**	**211,200,000**	**100.00**

Notes:

(1) The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places.

(2) Including (i) 36,228,570 Domestic Shares controlled by our Directors, Dr. Liang Dongke (梁棟科), Dr. Song Yuan (宋媛), Mr. Lin Sen (林森) and Mr. Wang Ruiqin (王瑞琴), and (ii) 15,415,178 Domestic Shares controlled by our substantial Shareholders, Ningbo Huaige Taiyi Equity Investment Partnership (Limited Partnership) (寧波懷格泰益股權投資合夥企業(有限合夥)), Ningbo Huaige Gongxin Equity Investment Partnership (Limited Partnership) (寧波懷格共信股權投資合夥企業(有限合夥)), Ningbo Huaige Health Investment Management Partnership (Limited Partnership) (寧波懷格健康投資管理合夥企業(有限合夥)), Mr. Wang Kai (王鍇) and Ms. Zhao Wei (趙威), collectively 51,643,748 Domestic Shares.

(3) Including the H Shares controlled by our substantial Shareholders: (i) 42,857,142 H Shares controlled by Shanghai Kindly Enterprise Development Group Co., Ltd. (上海康德萊企業發展集團股份有限公司), Shanghai Kindly Holding Group Co., Ltd. (上海康德萊控股集團有限公司), Kindly Holding Co., Ltd. (康德萊控股有限公司), Shanghai Gongye Investment Co., Ltd. (上海共業投資有限公司), Mr. Zhang Xianmiao (張憲淼), Ms. Zheng Aiping (鄭愛平) and Mr. Zhang Wei (張偉), (ii) 12,494,250 H Shares controlled by Ningbo Huaige Taiyi Equity Investment Partnership (Limited Partnership) (寧波懷格泰益股權投資合夥企業(有限合夥)), Ningbo Huaige Gongxin Venture Investment Partnership (Limited Partnership) (寧波懷格共信創業投資合夥企業(有限合夥)), Ningbo Huaige Health Investment Management Partnership (Limited Partnership) (寧波懷格健康投資管理合夥企業(有限合夥)), Mr. Wang Kai (王鍇) and Ms. Zhao Wei (趙威), and (iii) 18,844,200 H Shares controlled by Central Huijin Investment Ltd., China Orient Asset Management (International) Holding Limited, China Orient International Fund Management Limited, China Orient Multi-Strategy Master Fund and China Orient Enhanced Income Fund, collectively controlling 74,195,592 H Shares.

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC
22 January 2026

As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Dr. Song Yuan, Mr. Wang Ruiqin, Ms. Chen Hongqin and Mr. Zhang Hong as non-executive Directors, and Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.

* *For identification purposes only*